The Centers for Medicare & Medicaid Services will launch a Medicaid payment model next fall that aims to improve care and reduce expenditures for pregnant and postpartum women with opioid use disorders.
Oct 3, 2018
The Senate today passed by a vote of 98-1 the SUPPORT for Patients and Communities Act, the final House and Senate agreement on legislation to address the opioid crisis. Approved by the House last week, the legislation includes an AHA-supported provision that would allow states to receive federal…
Sep 28, 2018
The House of Representatives today passed by a vote of 393-8 the final version of the Opioid Crisis Response Act (H.R. 6).
Sep 19, 2018
More than 100 organizations, including the AHA, yesterday urged House and Senate leaders to include the Overdose Prevention and Patient Safety Act (H.R. 6082) in the final agreement on opioid legislation.
Sep 18, 2018
The Senate Sept. 17 passed the Opioid Crisis Response Act, a substitute amendment to the House-passed opioid package (H.R. 6).
Sep 14, 2018
The House and Senate conference committee yesterday approved legislation that would provide $178.1 billion in discretionary funding for the departments of Defense, Labor, Health and Human Services, and Education in fiscal year 2019 and extend current funding levels for other federal programs until…
May 15, 2020
The National Academies of Sciences Engineering, and Medicine released recommendations for improving outcomes and metrics associated with four grant programs funded by the Substance Abuse and Mental Health Services Administration to help reduce opioid-related harm and promote recovery from substance…
May 6, 2020
In this podcast, Jay Bhatt, former senior vice president and chief medical officer of the AHA, Victor Dzau, president of the National Academy of Medicine, and Ruth Katz, vice president and the executive director of the Health, Medicine, and Society Program at the Aspen Institute discuss how they…
Apr 27, 2020
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM) Model, due to COVID-19.